Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy

Scott H. Okuno, Charles O. Woodhouse, Charles L. Loprinzi, Jeff A. Sloan, Beth I. LaVasseur, Danette Clemens-Schutjer, Debra Swan, Claudia Axvig, Larry P. Ebbert, Maria R.B. Tria Tirona, John C. Michalak, Nancy Pierson

Research output: Contribution to journalArticle

61 Scopus citations


Mucositis is a prominent dose-limiting toxicity associated with 5-FU- based chemotherapy. On the basis of preliminary data suggesting that the amino acid glutamine could alleviate this problem, the authors developed this trial. Patients scheduled to receive their first 5-FU-based chemotherapy regimen were selected for study. Following stratification, patients were randomized, in a double-blind manner, to receive oral glutamine or a placebo preparation in a prophylactic manner. Patients in both groups were given oral cryotherapy before chemotherapy and were evaluated for mucositis by standard physicians' evaluation and by a self-report instrument. Sixty-six patients were randomized to receive glutamine and 68 to receive the placebo preparation. There were no significant differences or substantial trends in the mucositis scores between the two study arms as measured by either the physicians or the patients. It was concluded that the dose and schedule of glutamine used in this clinical trial does not alleviate 5-FU-induced mucositis.

Original languageEnglish (US)
Pages (from-to)258-261
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number3
StatePublished - Jun 1999



  • 5-FU chemotherapy
  • Mucositis
  • Placebo-controlled trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this